Coeptis Therapeutics Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
| ITEM 9B. | OTHER INFORMATION |
|---|
10b5-1 Plans
Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or may represent a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).
On May 21, 2025, Daniel Yerace, our Vice President of Operations and a member of our Board of Directors, adopted a Rule 10b5-1 trading plan. Mr. Yerace’s Rule 10b5-1 trading plan provides for an active term commencing on August 31, 2025, and ending no later than February 11, 2027, for the sale of up to 20,000 shares of common stock of the Company.
Insider Trading Policy
The Company has adopted insider trading policies and procedures governing the purchase, sale, and other disposition of its securities, which has been included as an exhibit to this report and has been posted to the investors and media/corporate governance section of the Company’s corporate website (www.coeptistx.com).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.